Introduction
============

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the backbone therapy for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) [@B1]. Historically, reduced-intensity conditioning (RIC) regimens prior to allo-HSCT were typically the strategy in older patients or younger patients with complicated comorbidities that are intolerable of myeloablative conditioning (MAC) regimens. However, ongoing interest has been shown in RIC regimens as consolidation therapy due to lower NRM and comparable survival, which were reported to be performed in two-thirds of transplanted patients in the past two decades [@B2]-[@B4]. A series of retrospective studies have drawn contradictory conclusions about the optimum conditioning intensity of younger AML/MDS patients [@B5]-[@B11]. The variability in age, performance status, and different comorbidities interfere with the ability to isolate the effects of conditioning intensities on outcomes.

To date, RIC allogeneic HSCT is a feasible treatment option for AML patients aged 60 years or older in the most-updated NCCN clinical practice guidelines (V2.2020) [@B12] still, for younger patients, there is a lack of high-level evidence for the use of RIC regimens [@B13]. Therefore, we conducted a timely systematic review and meta-analysis of recent randomized controlled trials (RCTs) to provide quantitative evidence on the overall efficacy and toxicity of RIC versus MAC in younger adults with AML or MDS.

Methods
=======

Searching strategy
------------------

According to the recommendations of the Cochrane Collaboration [@B14], [@B15], we retrieved articles from PubMed, Medline, Embase, and Google scholar from their inception until February 25, 2020. Abstracts from the conference proceedings, ongoing and unpublished trials in <https://www.clinicaltrials.gov> and the bibliographies of other relevant reviews were also manually identified.

We used a combination of corresponding keywords: "allogeneic hematopoietic stem cell transplantation", "reduced-intensity", "myeloablative", "acute myeloid leukemia" and "myelodysplastic syndromes".

Definitions of outcomes
-----------------------

The primary outcomes included overall survival (OS) and progression-free survival (PFS). The secondary outcomes consisted of non-relapse mortality (NRM), relapse incidence (RI), incidence of acute graft-versus-host disease (aGVHD), and chronic GVHD (cGVHD). The concept of PFS covered relapse-free survival, disease-free survival and leukemia-free survival. Similarly, the concept of NRM included transplant-related mortality (TRM).

Selection criteria and study selection
--------------------------------------

We included all comparative studies that met the following criteria: (1) RCTs included AML/MDS patients in complete remission who received either RIC or MAC; (2) the study reported sufficient patient demographics and outcomes.

To perform a systematic and comprehensive assessment, we combined all the multiple publications. Two investigators (Ma and Shi) selected the studies independently. Any discrepancy regarding eligibility was solved by consulting the senior investigator (Hu).

Data extraction and quality assessment
--------------------------------------

Two investigators (Ma, Shi) independently extracted the following information from each eligible study: characteristics (first author, year of the last publication, country, sample size, follow-up time, participant numbers of each group, period of enrollment, recruitment period), participant characteristics(sex, the median age at enrollment, diagnosis), intervention details (conditioning regimens, transplantation details) and outcomes. We contacted all corresponding authors for insufficient data in the articles. We assessed the methodological bias of the included trials by the Cochrane Collaboration\'s tool [@B16]. The senior author (Hu) assessed all disagreements in bias.

Data synthesis
--------------

Discontinuous data were pooled and calculated as odds ratios (OR) by using a 95% confidence interval (CI). If the publications did not provide data at a particular time point but curves, we used the methods reported by Tierney [@B17] and Parmer [@B18].

The summary effect estimates of OR for individual RCTs are indicated by solid squares, with a size proportional to the sample size and the number of events. Horizontal lines indicate 95% confidence interval. The diamonds indicate CIs for pooled effects, with the size of the box relating to the weight of the study. We assessed the heterogeneity among studies by the Q test (P\<0.05 to be indicative of statistically significant) and Higgins I^2^ parameters (25-50%, 50-75%, and \>75% were divided into low, moderate, and high heterogeneity) [@B19]. As indicated by DerSimonian and Laird [@B20], if I^2^ ≥ 50%, we chose the random-effect model; otherwise, we used the fixed-effect model. In the sensitivity analysis, the origin of heterogeneity was evaluated by repeating the meta*-*analysis after removing one study at a time. Moreover, we conducted subgroup analyses by diagnoses with the data available in included RCTs.

All statistical analyses were performed using Review Manager 5.3. All tests were 2-sided, and P\<0.05 was considered statistically significant.

Results
=======

Literature search and study characteristics
-------------------------------------------

Figure [1](#F1){ref-type="fig"} summarized the processes of study selection. After two rounds of careful screening and hand searches, 4 RCTs [@B21]-[@B24] reported in 7 publications were initially selected for this systematic review, including two abstract proceedings presenting long term follow-ups [@B25], [@B26] and an updated report [@B27] of the previously published one [@B22], [@B23]. We excluded two non-randomized prospective studies [@B28], [@B29].

Table [1](#T1){ref-type="table"} depicts the main characteristics of the included RCTs. Among them, three studies were performed in Europe and one in the United States. All included studies were published from 2013 to 2018. Altogether, 633 patients were randomized to be treated with either RIC (319 \[50.4%\]) or MAC (314 \[49.6%\]). Four hundred fifty-four patients were diagnosed as AML, 169 were MDS, and the others were CML or missing. Three RCTs [@B21]-[@B23] applied a uniform conditioning regimen in each arm and a uniform GVHD prophylaxis regimen, whereas several choices were available in the trial of Scott et al. [@B24]. The reported enrolled patients ranged in age from 18 to 66 years, and the median ages of each eligible study varied from 44 to 54.8.

Risk of bias
------------

According to the Cochrane Handbook, the overall bias risk of these RCTs was judged to be low to moderate (Figure [2](#F2){ref-type="fig"}). All RCTs reported the randomization details. Due to the special nature of transplantation, none of the four studies used double-blind methods. The outcomes of 2 trials [@B24], [@B27] were assessed with a low risk of bias, and missing data were described [@B24], [@B27]. All four studies were free of selective outcomes reporting. Four trials were judged to have a low risk of other bias.

Effect on overall survival
--------------------------

OS rates were all extractable from the survival curves in 4 RCTs (four for OS at 1 and 2 years, three for 4 [@B26], [@B27] and 5 years [@B27], Figure [3](#F3){ref-type="fig"}A). Specifically, two of them were from the updated abstracts [@B25], [@B26]. The rates of OS at 1, 2 and 4 years were similar between patients who received RIC and those who received MAC (OR = 0.78, 95% CI 0.27-2.24, P=0.65, I^2^=84%; OR=1.27, 95% CI 0.68-2.38, P=0.45, I^2^=64%; OR=1.01, 95% CI 0.42-2.38, P=0.99, I^2^=77%). However, OS was statistically significantly better with RIC instead of MAC at 5 years (OR=1.69, 95% CI 1.10-2.59, P=0.02, I^2^=0%), in line with the tendency in the second-largest RCT [@B27] that RIC achieved similar OS (61% at 3 years, 60% at 10 years) but MAC resulted in significantly lower survival at 10 years (47%) compared to that at 3 years (58%). Three trials presented comparable OS at the end of the study except one [@B26], which reported better OS for MAC at 4 years (65% vs. 49%, p=0.02). Accounting for the moderate and high heterogeneities in subgroups at 2 and 4 years, the I^2^ was valued 0% after repeating the meta*-*analysis removing Scott et al.\'s study.

Effect on progression-free survival
-----------------------------------

As shown in Figure [3](#F3){ref-type="fig"}B, PFS data, which comprised a total of 596 patients, were provided at 1, 2, and 4 years, while data from 361 patients were analyzed at 5 years. The pooled ORs were comparable: 0.71 (95% CI 0.28-1.80; P=0.47) at 1 year, 0.81(95% CI 0.34-1.92, P=0.63) at 2 years, 0.83(95% CI 0.35-1.98, P=0.67) at 4 years and 1.30(95% CI 0.85-1.99, P=0.23) at 5 years. Similar to OS, heterogeneity at 1, 2, 4 years (I^2=^85%) disappeared when Scott et al.\'s study was ruled out.

Effect on non-relapse mortality
-------------------------------

All studies, including 633 patients, reported data on NRM at 1, 2, 5 years. As depicted in Figure [4](#F4){ref-type="fig"}A, the combined ORs for 1, 2, 5-year NRM were 0.45 (95% CI 0.27-0.75; P=0.002), 0.47 (95% CI 0.30-0.75; P=0.001) and 0.48 (95% CI 0.31-0.75; P=0.001), respectively. Without heterogeneity in all subgroups (I^2^=0%), additional subgroup or sensitivity analyses were unnecessary. Accordingly, there was strong evidence for the reduced incidence of NRM in the RIC intervention group.

Effect on relapse incidence
---------------------------

Pooled analysis of all studies presented no statistically difference between two interventions among different follow-up durations (1 year: 2.11, 95% CI 0.67-6.67, P=0.20; 2 years: 1.43, 95% CI 0.43-4.70, P=0.56; 5 years: 1.27, 95% CI 0.41-3.94, P=0.68; Figure [4](#F4){ref-type="fig"}B). While similar relapse risk was found in the other three trials, only one study [@B26] reported higher relapse incidence, contributing to the high heterogeneity in three subgroups (I^2^=80%, 87%, 88%).

Effect on graft-versus-host disease
-----------------------------------

As shown in Figure [5](#F5){ref-type="fig"}, cumulative incidences of acute GVHD grade II to IV and grade III to IV were evaluated in all studies for 633 patients and three of four studies for 438 patients, respectively. The grade II to IV aGVHD were significantly less frequent in the RIC group (OR 0.62; 95% CI 0.44-0.87; P=0.006) compared with the MAC group. There was no statistically significant heterogeneity among the trials (I^2^=0%). Regarding more severe aGVHD (grades III to IV), there was a non-significant trend between the two intensities. (OR 0.58; 95% CI 0.32-1.05; P=0.07) with low heterogeneity among the trials (I^2^=42%). At the end of follow-up, the cumulative incidence of overall and extensive chronic GVHD was obtained in four and three studies, respectively. There was evidence for significantly lower rates of overall cGVHD in the RIC arm (OR 0.71; 95% CI 0.51-1.00, P=0.05) with moderate heterogeneity (I^2^=50%). However, the available evidence from three trials including 508 patients was not sufficiently powered to show a statistically significant difference in extensive cGVHD between the two intervention groups (OR 1.12; 95% CI 0.72-1.76, P=0.61) with extremely low (I^2^=0%) heterogeneity.

Subgroup analyses focusing on AML
---------------------------------

Treatment effects were evaluable for 450 patients with AML from three of four trials [@B21], [@B23], [@B24]. As presented in Figure [6](#F6){ref-type="fig"}, OS and PFS were not significantly different between the two intensity regimens, with pooled OR of 0.88 (95% CI 0.34-2.26, P=0.79) and 1.16 (95% CI 0.41-3.25, P=0.78), respectively. Besides, the comprehensive analyses from two trials [@B21], [@B23] indicated a potential improvement in NRM and grade II-IV aGVHD for RIC compared with MAC (OR 0.59; 95% CI 0.30-1.14, P=0.12 for NRM, OR 0.59; 95% CI 0.31-1.11, P=0.10 for grade II-IV aGVHD), and the incidences of relapse and overall cGVHD were comparable at the end of the study. Furthermore, in risk stratification by cytogenetics, two studies [@B23], [@B24] reported comparable outcomes for intermediate-risk patients, while the smallest RCT [@B21] indicated better PFS in the RIC group. For high-risk patients with AML, Scott et al. [@B24] claimed worse OS with RIC, whereas Rinden et al. [@B21] showed a PFS benefit and Bornhäuser et al. presented no significant difference in OS, PFS, RI, NRM between two arms (Table [2](#T2){ref-type="table"}).

Subgroup analyses focusing on MDS
---------------------------------

As shown in Figure [7](#F7){ref-type="fig"}, two out of four trials involving 183 patients with MDS reported OS, PFS, and relapse incidence. Likewise, none of the pooled results was statistically significant between the two conditioning intensities. For NRM, aGVHD and cGVHD, one study [@B22] provided similar effects in two arms, whereas the other [@B24] only reported them for AML and MDS patients as a whole, suggesting better outcomes in RIC regimens. The trial conducted by Kroger et al. [@B22] stratified cytogenetic risks into three levels and indicated that RIC in the low-risk cytogenetic group resulted in lower NRM but similar NRM in intermediate- and high-risk groups. In the BMT CTN 0901 [@B24], no significant difference was found in OS for standard-risk patients, while RIC in the high-risk cytogenetic group resulted in worse OS (Table [3](#T3){ref-type="table"}).

Discussion
==========

In this systematic review, we included all high-quality RCTs and yielded two main conclusions: Regarding toxicity, we noted that RIC was associated with a lower risk of NRM and GVHD. Besides, the survival and relapse rates of the two regimens were comparable. Although not all studies present five-year data, we have found that the RIC group had a better five-year OS. For subset analyses of AML patients, we found that RIC had similar survival and relapse risk compared with MAC, with a trend towards less NRM and grade II-IV GVHD in RIC regimens. For patients with MDS, available data indicated comparable outcomes in OS, PFS and relapse.

The risk bias of published RCTs was evaluated as low to moderate with randomized settings. Avoiding the selection bias and recalling bias, this meta-analysis provides the highest current level of evidence for the question in hand for AML and MDS patients. Although previous systematic reviews [@B30]-[@B32] have reported the similar results as our meta-analysis except for higher relapse rate, such studies mainly included retrospective studies, in which RIC was generally used for older individuals while MAC for younger patients. Also, the individualized decisions of different attending physicians may inevitably interfere with the conclusions. The advantage of NRM and GVHD reminds us that the RIC regimen is a valuable choice for patients who cannot tolerate high-intensity conditioning [@B33]-[@B35]. A current retrospective study revealed that MAC improves outcomes for AML and MDS patients with relatively lower disease risk index (DRI) but has a similar impact on patients with higher DRI [@B36]. Nowadays, more and more novel strategies were being successfully used as subsequent maintenance therapy after allo-HSCT, which significantly reduced the recurrence of allo-HSCT recipients receiving RIC regimens [@B37]-[@B39]. Additionally, the long-term GVHD/relapse-free survival was also comparable in two arms for AML patients [@B40]-[@B42] but superior in RIC arm for MDS patients [@B43].

For AML patients, RIC regimens have demonstrated at least non-inferior survival and a trend of less toxicity. A sizeable observational analysis by the EBMT focusing on 2974 middle-aged (40-60) patients with AML [@B44] demonstrated that RIC resulted in higher OS and comparable RI in low-risk AML. However, the OS was similar and RI was higher in the intermediate- or high-risk patients. Additionally, the NRM was lower in all three cytogenetic risk groups, which was consistent with our findings in Figure [4](#F4){ref-type="fig"}A. From another perspective, patients in CR1 with high-risk cytogenetics or with MRD positive in genomics or multi-parameter flow cytometry (MFC) can benefit more from the MAC regimens [@B45]-[@B47].

As for the effect on MDS patients, we took account of the updated reports with longer follow-up [@B25], [@B26] and yielded results consistent with the previous studies [@B22], [@B24], [@B48]. Furthermore, we systematically reviewed that RIC resulted in less NRM in low-risk groups [@B22] but better OS in high-risk groups [@B24] for MDS patients. Besides, the genomics of MDS might have the potential to influence the optimal selection of conditioning intensity. CIBMTR research revealed a higher relapse rate in MDS patients with RAS pathway mutations only after RIC. In contrast, conditioning intensity didn\'t make a difference in outcomes for TP53-mutated MDS [@B49].

Of note, only one included clinical trial published by Scott and colleagues [@B26] reported worse outcomes of RIC. By contrast, the other three RCTs supported RIC for at least similar survival and less toxicity. Though the most weight was assigned to study by Scott BL et al. in the meta-analysis because of its largest sample size, there was still no evidence that reduced-intensity conditioning was inferior to MAC in either AML or MDS. Further sensitivity analysis confirmed the robustness of the results. There are several possible sources of heterogeneity. It was noteworthy that the trial by Scott et al. was the only one that included patients beyond CR2 and applied multiple choices of conditioning regimens and GVHD prophylaxis regimens in each intensity arm. Besides, it could conceivably be hypothesized that the heterogeneity could partially derive from the different distributions of cytogenetic risks and potential MRD in included RCTs.

Although stringent criteria were applied to identify and include studies for our meta-analysis, inherently, like any meta-analysis, there are some limitations in our study. Firstly, although stringent criteria have been applied in our meta-analysis, the baseline characteristics were impractical to be unified among studies. For example, one of the studies [@B21] has only enrolled 18 and 19 patients in two arms, respectively. The study published by Scott et al. included patients beyond CR2, while others restricted to the first or second CR. Secondly, the limited number of RCTs may have an impact on the statistical power of our results. Finally, regimens of different intensities were not completely uniform in included RCTs, though we tried to decrease the bias through heterogeneity analysis and got reliable conclusions.

Our results indicate that RIC is not inferior to MAC for AML patients with comparable post-transplantation survival, relapse risk, as well as potential advantages in NRM and GVHD. For MDS patients, neither survival nor relapse rate was significantly different. Based on the above results, it might be concluded that RIC is a feasible treatment option for adults with AML or MDS younger than 66 years, particularly those with intermediate-risk disease. Future RCTs incorporating of risk stratifications are warranted to guide the optimal decision under certain conditions.
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###### 

Characteristics of studies included in the meta-analysis

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                          Bornhäuser 2018 [@B23], [@B27]   Kroger 2018 [@B22], [@B25]       Ringden 2013 [@B21]                                     Scott 2020 [@B24], [@B26]                                                                                                                                                                       
  -------------------------------- ------ -------------------------------- -------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------ ------------------------------ ------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Number of centers                       13                               18                               1                                                       32                                                                                                                                                                                              

  Conditioning\                           RIC                              MAC                              RIC                                                     MAC                                                     RIC                            MAC                            RIC                                                                       MAC
  regimen                                                                                                                                                                                                                                                                                                                                                           

  Protocol                                Flu (150mg/m³) + TBI (8 Gy)      TBI (12Gy) + Cy (120 mg/kg)      Flu (150mg/m³) + Bu (8mg/kg orally or 6.4 mg/kg i.v.)   Bu (16mg/kg orally or 12.8mg/kg i.v.) + Cy (120mg/kg)   Flu (180mg/m³) + Bu (8mg/kg)   Bu (16mg/kg) + Cy (120mg/kg)   Flu (120 to 180mg/m^2^) + Bu (≤8 mg/kg orally or 6.4mg/kg i.v.); FluMel   Flu (120-180mg/m^2^) + Bu (16mg/kg orally or 12.8 mg/kg i.v.); Bu + Cy (120mg/kg); TBI (12-14.2Gy) + Cy.

  No. of cases                            99                               96                               65                                                      64                                                      18                             19                             137                                                                       135

  Male,%                                  43 (43%)                         47 (49%)                         38 (59%)                                                8 (23%)                                                 12 (63%)                       11 (79%)                       67 (49%)                                                                  76 (56%)

  Median age(range),y                     44 (18-60)                       45 (18-60)                       51 (22-63)                                              50 (19-64)                                              46 (26-61)                     45 (22-58)                     54.8 (21.9-65.9)                                                          54.8 (21.9-66)

  Diagnosis                               AML                              MDS: 115; sAML: 12; missing: 2   AML: 29; CML: 8                                         AML: 218; MDS: 54                                                                                                                                                                               

  GVHD prophylaxis                        CsA /MTX                         CsA/MTX                          CsA/MTX                                                 CNI/MMF, CNI/MTX, Tac/Siro                                                                                                                                                                      

  Donor type                       MRD    59                               58                               16                                                      17                                                      7                              7                              58                                                                        57

  MUD                              28     24                               38                               36                                                      11                                                      12                             58                             66                                                                        

  Other                            12     14                               11                               11                                                      0                                                       0                              21                             12                                                                        

  Graft source                     PBSC   90                               90                               59                                                      61                                                      17                             16                             123                                                                       127

  BM                               9      6                                6                                3                                                       1                                                       3                              14                             8                                                                         

  Recuitmentperiod                        2004-2009                        2004-2012                        NR                                                      2011-2014                                                                                                                                                                                       

  Median follow-up(range), month          119\                             119\                             72                                                      75                                                      40.8 (6-104.4)                 62.4\                          50                                                                        50
                                          (102-137)                        (102-138)                                                                                                                                                                       (14.4-111.6)                                                                                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: RIC, reduced-intensity conditioning; MAC, myeloablative conditioning; Flu, fludarabine; TBI, total-body irradiation; Cy, cyclophosphamide; Bu, busulfan; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; sAML, secondary acute myeloid leukemia; CML, chronic myeloid leukemia; GVHD, graft-versus-host disease; CsA, cyclosporine A; MTX, methotrexate; MMF, mycophenolate mofetil; CNI, calcineurin inhibitor; MRD, matched related donor; MUD, matched unrelated donor; PBSC, peripheral blood stem cell; BM, bone marrow.

###### 

Disease status, cytogenetic risk stratification and outcomes for acute myeloid leukemia

                    Disease status                          Risk stratification   RIC                                                                 MAC   Outcomes
  ----------------- --------------------------------------- --------------------- ------------------------------------------------------------------- ----- --------------------------------------------------------------------
  Bornhäuser 2018   CR1; \<5% marrow myeloblasts pre-HSCT   Intermediate§         77                                                                  70    No significant difference in OS, PFS, RI, NRM
  High¶             22                                      26                    No significant difference in OS, PFS, RI, NRM                             
  Rinden 2013       CR1 or CR2                              Intermediate          11                                                                  12    3-year PFS was better in RIC group than in MAC group (90% vs. 75%)
  High              3                                       3                     3-year PFS was better in RIC group than in MAC group (67% vs. 0%)         
  Scott 2020\*      CR; \<5% marrow myeloblasts pre-HCT     Intermediate†         71                                                                  74    No significant difference in OS
  High‡             61                                      54                    MAC was associated with a significant OS benefit.                         

RIC, reduced-intensity conditioning; MAC, myeloablative conditioning; CR, complete remission; OS, overall survival; PFS, progression-free survival; RI, relapse incidence; NRM, non-relapse mortality.

§Intermediate=normal and non-high risk, including normal karyotype and other intermediate abnormalities.

¶Including the following cytogenetic abnormalities: +8; Complex (≥3 aberrations); -5, -7, del(5q); Inv(3), t(3;3); t(6;11), t(11;19); t(6;9).

†Defined according to the Eastern Cooperative Oncology Group/SWOG cytogenetic classification schema.

‡Including unfavorable risk cytogenetics according to the Eastern Cooperative Oncology Group/SWOG, FLT3 mutation regardless of accompanied cytogenetic risk.

\*Data are for patients with acute myeloid leukemia and myelodysplastic syndromes combined.

###### 

Disease status, cytogenetic risk stratification and outcomes for myelodysplastic syndrome

                 Disease status                                                     Risk stratification   RIC                                                 MAC   Outcomes
  -------------- ------------------------------------------------------------------ --------------------- --------------------------------------------------- ----- -----------------------------------------
  Kroger 2018    MDS: 115; sAML: 12; missing: 2; \<20% marrow myeloblasts pre-HCT   Low                   28                                                  24    RIC resulted in significantly lower NRM
  Intermediate   13                                                                 17                    No significant difference in NRM                          
  High           18                                                                 17                    No significant difference in NRM                          
  Scott 2020\*   \<5% marrow myeloblasts pre-HCT                                    Intermediate          71                                                  74    No significant difference in OS
  High‡          61                                                                 54                    MAC was associated with a significant OS benefit.         

RIC, reduced-intensity conditioning; MAC, myeloablative conditioning; CR, complete remission; MDS, myelodysplastic syndrome; sAML, secondary acute myeloid leukemia; OS, overall survival; NRM, non-relapse mortality.

‡intermediate-II or high-risk disease per the International Prognostic Scoring System.

\*Data are for patients with acute myeloid leukemia and myelodysplastic syndromes combined.
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